All Phenotypes Tg(NPHS2-rtTA2*M2)1Jbk MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Tg(NPHS2-rtTA2*M2)1Jbk
transgene insertion 1, Jeffrey B Kopp
MGI:3629962

Summary

6 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor^tm1Sor Tg(NPHS2-rtTA2M2)1Jbk/Tg(NPHS2-rtTA2M2)1Jbk Tg(tetO-cre)LC1Bjd/Tg(tetO-cre)LC1Bjd	involves: 129S4/SvJaeSor * BALB/c * C57BL/6 * FVB/N	MGI:6402037
cn2	Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor^tm1Sor Tg(NPHS2-rtTA2M2)1Jbk/Tg(NPHS2-rtTA2M2)1Jbk Tg(tetO-cre)LC1Bjd/0	involves: 129S4/SvJaeSor * BALB/c * C57BL/6 * FVB/N	MGI:6402038
cn3	Wt1^tm1.1Ceng/Wt1^tm1.1Ceng Tg(tetO-cre)LC1Bjd/0 Tg(NPHS2-rtTA2*M2)1Jbk/0	involves: BALB/c * C57BL/6 * FVB/N	MGI:5512664
cx4	Lama5^tm3Jhm/Lama5^tm3Jhm Tg(NPHS2-rtTA2*M2)1Jbk/0 Tg(tetO-LAMA5)1Jhm/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * FVB/N	MGI:5432562
cx5	Hprt1^{tm1(tetO-EGFP/Rac1)Shaw}/Y Tg(NPHS2-rtTA2M2)1Jbk/0	involves: 129S4/SvJae * C57BL/6 * FVB/N	MGI:5559183
cx6	Tg(NPHS2-rtTA2*M2)1Jbk/0 Tg(tetO-RNAi:Vegfa)#Atuf/0	involves: FVB	MGI:5446897

Allelic Composition	Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor^tm1Sor Tg(NPHS2-rtTA2M2)1Jbk/Tg(NPHS2-rtTA2M2)1Jbk Tg(tetO-cre)LC1Bjd/Tg(tetO-cre)LC1Bjd
Genetic Background	involves: 129S4/SvJaeSor * BALB/c * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^tm1Sor mutation (8 available); any Gt(ROSA)26Sor mutation (942 available)
Tg(NPHS2-rtTA2*M2)1Jbk mutation (1 available)
Tg(tetO-cre)LC1Bjd mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

aneuploidy ( J:285673 )

• in primary podocyte cell cultures from doxycycline-treated mice

homeostasis/metabolism

increased urine protein level ( J:285673 )

• in doxycycline-treated mice

increased susceptibility to xenobiotic induced morbidity/mortality ( J:285673 )

• within the first 3 weeks following treatment with a high dose (50 ug/g) of doxycycline

• however, a lower doxycycline dose (15 ug/g) that produces FSGS does not affect lethality

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:285673 )

• within the first 3 weeks following treatment with a high dose (50 ug/g) of doxycycline

• however, a lower doxycycline dose (15 ug/g) that produces FSGS does not affect lethality

renal/urinary system

increased urine protein level ( J:285673 )

• in doxycycline-treated mice

podocyte foot process effacement ( J:285673 )

• with vacuolization after 10 days in mice treated with doxycycline

decreased podocyte number ( J:285673 )

• reduced density in mice treated with doxycycline

glomerulosclerosis ( J:285673 )

• from 3 weeks of age, doxycycline-treated mice exhibit focal segmental glomerulosclerosis (FSGS) with adhesions, segmental accumulation of matrix, capillary hyalinosis, loss of capillaries, and declining glomerular numbers through 13 weeks unlike control mice

• however, mice do not develop FSGS when doxycycline is administered antenatally or at 10 and 11 days after birth or when mice are treated with a low dose of doxycycline (1.5 ug/g)

decreased renal glomerulus number ( J:285673 )

• in doxycycline-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
focal segmental glomerulosclerosis		DOID:1312	OMIM:PS603278	J:285673

Allelic Composition	Gt(ROSA)26Sor^tm1Sor/Gt(ROSA)26Sor^tm1Sor Tg(NPHS2-rtTA2M2)1Jbk/Tg(NPHS2-rtTA2M2)1Jbk Tg(tetO-cre)LC1Bjd/0
Genetic Background	involves: 129S4/SvJaeSor * BALB/c * C57BL/6 * FVB/N

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

renal/urinary system

renal/urinary system phenotype ( J:285673 )

N	• doxycycline-treated mice do not exhibit focal segmental glomerulosclerosis

Allelic Composition	Wt1^tm1.1Ceng/Wt1^tm1.1Ceng Tg(tetO-cre)LC1Bjd/0 Tg(NPHS2-rtTA2*M2)1Jbk/0
Genetic Background	involves: BALB/c * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(NPHS2-rtTA2*M2)1Jbk mutation (1 available)
Tg(tetO-cre)LC1Bjd mutation (2 available)
Wt1^tm1.1Ceng mutation (0 available); any Wt1 mutation (34 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

renal/urinary system

albuminuria ( J:197989 )

• progressive in doxycycline-treated mice

glomerulosclerosis ( J:197989 )

• focal segmental glomerulosclerosis in doxycycline-treated mice

homeostasis/metabolism

albuminuria ( J:197989 )

• progressive in doxycycline-treated mice

Allelic Composition	Lama5^tm3Jhm/Lama5^tm3Jhm Tg(NPHS2-rtTA2*M2)1Jbk/0 Tg(tetO-LAMA5)1Jhm/0
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lama5^tm3Jhm mutation (0 available); any Lama5 mutation (153 available)
Tg(NPHS2-rtTA2*M2)1Jbk mutation (1 available)
Tg(tetO-LAMA5)1Jhm mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

renal/urinary system

renal/urinary system phenotype ( J:185850 )

N	• when doxycycline is administered from E12 to E15 to pregnant animals, offspring do not develop proteinuria or hematuria, with no kidney disease at least to 6 months of age

Allelic Composition	Hprt1^{tm1(tetO-EGFP/Rac1)Shaw}/Y Tg(NPHS2-rtTA2M2)1Jbk/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hprt1^{tm1(tetO-EGFP/Rac1*)Shaw} mutation (0 available); any Hprt1 mutation (1274 available)
Tg(NPHS2-rtTA2*M2)1Jbk mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

renal/urinary system

increased urine protein level ( J:206088 )

• after 2 days of doxycycline treatment

• however, proteinuria abates 1 week post-induction

podocyte foot process effacement ( J:206088 )

• segmental in doxycycline-treated mice

homeostasis/metabolism

increased urine protein level ( J:206088 )

• after 2 days of doxycycline treatment

• however, proteinuria abates 1 week post-induction

Allelic Composition	Tg(NPHS2-rtTA2*M2)1Jbk/0 Tg(tetO-RNAi:Vegfa)#Atuf/0
Genetic Background	involves: FVB

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(NPHS2-rtTA2*M2)1Jbk mutation (1 available)
Tg(tetO-RNAi:Vegfa)#Atuf mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

renal/urinary system

decreased urine creatinine level ( J:189626 )

• in tamoxifen-treated mice

increased urine protein level ( J:189626 )

• in tamoxifen-treated mice

podocyte foot process effacement ( J:189626 )

• in tamoxifen-treated mice

abnormal renal glomerulus basement membrane morphology ( J:189626 )

• delamination in tamoxifen-treated mice

abnormal renal glomerulus morphology ( J:189626 )

• tamoxifen-treated mice exhibit decreased glomerular volume, mesangiolysis and glomerular microaneurisms compared with wild-type mice

abnormal glomerular filtration barrier morphology ( J:189626 )

• tamoxifen-treated mice exhibit damaged glomerular filtration barrier with swelling, vacuolization and decreased fenestration of endothelial cells; glomerular basement membrane lamination, expansion of the lamina densa, irregular thickening and interdigitations of the endothelium surface; and podocyte foot process effacement compared with wild-type mice

mesangiolysis ( J:189626 )

• in tamoxifen-treated mice

kidney failure ( J:189626 )

• in tamoxifen-treated mice

homeostasis/metabolism

increased circulating creatinine level ( J:189626 )

• in tamoxifen-treated mice

decreased urine creatinine level ( J:189626 )

• in tamoxifen-treated mice

increased urine protein level ( J:189626 )

• in tamoxifen-treated mice

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/23/2024 MGI 6.23